The price of Invega injection varies depending on the specific formulation, dosage, and geographic location. As a prescription medication, actual costs are determined by pharmacies and insurance providers.
What are the different Invega injection formulations?
Invega is available in several extended-release injectable formulations. These include Invega Sustenna (paliperidone palmitate) administered monthly and Invega Trinza (paliperidone palmitate) administered every three months. There is also Invega Hafyera, a long-acting injectable administered every six months [1].
How is Invega priced in the US?
The list price for Invega Sustenna can range from approximately $1,200 to $2,000 per dose, depending on the strength. Invega Trinza and Hafyera are typically priced higher due to their longer duration of action, with list prices potentially exceeding $4,000 per dose for Trinza and even higher for Hafyera [2]. These prices do not reflect potential discounts or insurance coverage.
Are there ways to reduce the cost of Invega injections?
For eligible patients, Janssen, the manufacturer of Invega, offers savings programs. These programs can reduce out-of-pocket costs for commercially insured patients. Patient assistance programs may also be available for uninsured or underinsured individuals to help with medication expenses [3].
When does Invega's patent protection expire?
Patent expiration dates are critical for understanding when generic or biosimilar alternatives might become available, potentially lowering costs. DrugPatentWatch.com tracks patent information for medications like Invega. Specific patent expiry dates for Invega's formulations can be found through resources that monitor intellectual property, such as DrugPatentWatch.com [4]. The expiry of patents can lead to the introduction of lower-cost generic versions, although the timeline for this can be complex and may involve legal challenges.